DNA (Deoxyribonucleic acid) comprises the blueprints of life. Within the structure of DNA, there are codes which are required for the assembly of proteins and non-coding RNA; these molecular machineries are responsible for affecting the biological systems that are creating and maintaining life. By understanding the DNA sequence, researchers have been able to interpret the structure and function of proteins, RNA, and have also gained an understanding of the underlying causes of diseases. Next-Generation Sequencing (NGS) is a powerful platform that enables the sequencing of a large number of DNA molecules simultaneously. It is a high-throughput methodology that enables rapid sequencing of samples consisting of DNA or RNA base pairs. NGS supports a broad range of applications including, chromosome counting, gene expression profiling, molecular analysis, and detection of epigenetic changes. NGS is boosting discovery and enabling the personalized medicine future, also revolutionizing fields, such as, genetic diseases and clinical diagnostics with the capability to sequence multiple individuals at the same time. According to the European Bioinformatics Institute (EBI), next-generation sequencing is the catch-all term used to describe a number of modern sequencing technologies including, the roche 454 sequencing, illumina (solexa) sequencing, SOLiD sequencing, and ion torrent: proton / PGM sequencing.
The global NGS services market is primarily driven by factors, such as, plunging cost of sequencing, technological advancements in NGS, increasing requirement for skilled professionals for efficient sample preparation and analysis of NGS, exorbitant cost of sequencing infrastructure, and expansion in genome mapping programs. Moreover, rising applications in agrigenomics and oncology research and need for complex sequencing data analysis provides major opportunities for NGS service providers. However, installation of in-house sequencing facilities in hospitals and universities is anticipated to hinder the growth of next-generation sequencing (NGS) services market in the near future.
In terms of service type, the next-generation sequencing (NGS) services market can be segmented into targeted sequencing, exome sequencing, RNA sequencing, de novo sequencing, whole genome sequencing, ChIP-sequencing, methyl sequencing, and other services. Based on technology, the next-generation sequencing (NGS) services market can be classified into ion semiconductor sequencing (IOS), single molecule real time sequencing (SMRT), sequencing by synthesis (SBS), nanopore sequencing, and true single molecule sequencing (tSMS). In terms of application, the next-generation sequencing (NGS) services market can be divided into diagnostics, biomarker discovery, drug discovery, agriculture & animal research, and other applications. In terms of end-user, the next-generation sequencing (NGS) services market can be segmented into academic & research Institutes, hospitals & clinics, pharmaceutical & biotechnology industry, and others.
Based on geography, the next-generation sequencing (NGS) services market can be categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global market due to factors, such as, effective regulatory guidelines regarding approval and use of genetic tests, well-entrenched network of informatics, and strong presence of prominent leaders in the region. Moreover, increasing number of FDA approved genomic tests in the U.S., rising high burden of infectious and chronic diseases, growing R&D expenditure, and rising awareness regarding NGS services are driving the next-generation sequencing (NGS) services market in North America. Asia Pacific is expected to be the fastest growing market for NGS services due to factors, such as, growing population, increasing prevalence of diseases, initiatives taken by government toward public health maintenance, and rise in research and development in diagnostics.
Key players functioning in the global next-generation sequencing (NGS) services market are BGI, Illumina, Inc., Novogene Corporation, Veritas, QIAGEN, PerkinElmer Inc., Eurofins Scientific, Macrogen, Inc., Genotypic Technology Pvt Ltd, and SciGenom Labs Pvt. Ltd. For gaining competitive advantage in the market, these players are involved actively in different growth strategies, such as, partnerships, agreements, collaborations, and new product development.
Interested in this report?
Get a FREE Brochure now!
*Get Brochure (PDF) sent to your email within minutes
Get a free copy if the report you purchased is updated within 90 days